| 2019-07-08 16:06:42|
AZRX 16:06 07/08 07/08/19
AzurRx BioPharma begins Initiation of phase 2 clinical study for MS1819-SD
AzurRx BioPharma announced that it has initiated a Phase 2 clinical trial to investigate MS1819-SD in combination with standard porcine enzyme replacement therapy for patients with cystic fibrosis that suffer from severe exocrine pancreatic insufficiency, but continue to experience clinical symptoms of fat malabsorption despite taking the maximum daily dose of PERTs. The digestive standard of care for both CF and chronic pancreatitis patients with EPI are commercially-available PERTs. Ideally, a stable daily dose of PERT will enable CF patients to eat a normal to high-fat diet and minimize unpleasant gastrointestinal symptoms. In practice, however, a substantial number of CF patients do not achieve normal absorption of fat with PERTs. Achieving an optimal nutritional status, including normal fat absorption levels, in CF patients is important for maintaining better pulmonary function, physical performance and prolonging survival. Furthermore, a decline of body mass index around the age of 18 years predicts a substantial drop in lung function.